Inceptor Bio, a recently founded biotechnology company searching for cancer treatments, says it has raised $26 million from investors and is on the hunt for manufacturing space in the Triangle.
The startup was founded last year, but has remained under the radar while it searched for funding and potential gene therapy treatments to develop.
The company\’s founder and CEO, Shailesh Maingi, said Inceptor plans to license technology from universities and then move to commercialize it. The company has already inked a few deals, including one with UNC-Chapel Hill, though it declined to release specifics.
Inceptor\’s funding round was led by Kineticos Disruptor Fund, a life science investment vehicle managed by the Triangle-based consulting firm Kieticos. Maingi previously worked at Kineticos and is a veteran of the Triangle biotech scene.
\“We have a simple mission,\” Maingi said in a video interview, \“and the mission is to advance gene and cell therapies to cure cancer.\”


